Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Author(s): Long Peng , Tao Zeng , Enxi Quan , et al Added: 1 year ago

Cardiovascular Kidney Metabolic

Heart Failure
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 1 year ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

MI/ACS

Heart Failure
Multimodality Imaging in Hypertrophic Cardiomyopathy
Author(s): Daniel Escribano , Elena Díaz-Peláez , Victoria Delgado Added: 3 weeks ago

Imaging & Diagnostics

Electrophysiology & Arrhythmia
Heart Failure in Hypertrophic Cardiomyopathy
Author(s): Olives Nguyen , Daniel Kamna , Ahmad Masri Added: 3 months ago

Guidelines & Statements

Heart Failure
Innovative Strategies in Ischemic Heart Disease Management
Author(s): Shrilla Banerjee , Mirvat Alasnag , Marta Kałuzna-Oleksy , et al Added: 1 year ago
In this video, Dr Marta Kałużna-Oleksy is joined by Dr Mirvat Alasnag, Dr Shrilla Banerjee and Dr Michal Hawranek to discuss strategies for heart failure management, based on a presentation at the Prevention and Intervention meeting in 2024.The faculty discuss SCAD, MINOCA and holistic approaches to managing these conditions, including lifestyle factors, hypertension and diabetes. They outline… View more

Intervention

Prevention & Chronic Conditions
ESC 25: The ODYSSEY-HCM Study
Author(s): Milind Y Desai Added: 9 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more

Heart Failure
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 8 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
Hypertrophic Cardiomyopathy in the Spotlight: A Special Focus on Precision Diagnosis, Targeted Therapies & Risk Management
Author(s): Victoria Delgado Added: 1 month ago
This comprehensive educational programme, led by guest editor Prof Clara Ines Saldarriaga Giraldo, bridges the gap between the latest guidelines and clinical practice in the diagnosis and management of hypertrophic cardiomyopathy (HCM).Following the Special Collection in Cardiac Failure Review (CFR), hear more from the leading experts in these exclusive interviews for further insights on new… View more

Imaging & Diagnostics

Inherited and Congenital Cardiac Conditions
Author(s): Julian Gillmore , Margot K Davis , Ahmad Masri , et al Added: 1 year ago
First presented at ESC 2024, this on-demand programme sees Prof Julian Gillmore (University College London, London, UK) lead a distinguished faculty compromising of Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT).The faculty present recent epidemiological… View more

Heart Failure